Gastrinoma (Duodenal and Pancreatic)

  title={Gastrinoma (Duodenal and Pancreatic)},
  author={Robert T. Jensen and Bruno Niederle and E. Mitry and John K. Ramage and Th. Steinm{\"u}ller and Valerie Lewington and Aldo Scarpa and Anders Sundin and Aurel Perren and David Gross and Juan Manuel O'Connor and Stanislas A. Pauwels and G{\"u}nter Kl{\"o}ppel},
  pages={173 - 182}
a Digestive Diseases Branch, NIH, Bethesda, Md. , USA; b Division of General Surgery, Department of Surgery, Medical University of Vienna, Vienna , Austria; c Department of Hepatology and Gastroenterology, CHV A Pare Hospital, Boulogne , France; d Department of Gastroenterology, North Hampshire Hospital, Hampshire , UK; e Department of Surgery, Vivantes Humboldt Hospital, Berlin , Germany; f Department of Radiology, Royal Marsden Hospital, Sutton , UK; g Department of Pathology, Verona… 

Consensus Guidelines for the Management of Patients with Liver Metastases from Digestive (Neuro)endocrine Tumors: Foregut, Midgut, Hindgut, and Unknown Primary

This poster presents a poster presented at the 2016 European Congress of Nuclear Medicine, entitled “Advances in Nuclear Medicine and Pathology: Foundations of Surgeons’ Ethics and Practice, 2nd Ed.” in Amsterdam.

Consensus guidelines update for the management of functional p-NETs (F-p-NETs) and non-functional p-NETs (NF-p-NETs)

aDepartment of Surgery, San Raffaele Hospital, Università Vita e Salute, Milan, Italy bDepartment of Endocrine Oncology, University Hospital Uppsala, Sweden cDepartment of Pathophysiology, Div

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biotherapy

This work presents a meta-modelling study of the immune system’s role in the development of central giant cell granuloma, which is a type of cancer that is difficult to treat with conventional chemotherapy.

Gastric Neuroendocrine Tumor and Duodenal Gastrinoma With Chronic Autoimmune Atrophic Gastritis.

This first report of synchronous duodenal gastrinoma and gastric NET in the setting of autoimmune CAG can broaden the understanding of gastricNET pathophysiology.

Misdiagnosed gastrinoma: A case report

A rare case of gastrinoma located in the tail of the pancreas of a female patient under medical examination, who exhibited no clinical symptoms, is reported, which confirmed as a malignant pancreatic neuroendocrine carcinoma with liver metastases.

Incidence and Prognosis of Primary Gastrinomas in the Hepatobiliary Tract

Primary gastrinomas of the hepatobiliary tract are uncommon, but the liver or bile duct system is the second most frequent extraduodenopancreatic primary location (after the lymph nodes).

Multiple giant duodenal ulcers associated with duodenal gastrinoma

When it is difficult to detect the tumor directly by conventional endoscopy, it is recommended that attempts be made to detection the tumor by inverting a transnasal endoscope into the duodenal bulb.

Duodenal neuroendocrine neoplasms: a still poorly recognized clinical entity

The multi-disciplinary approach and the preservation of the quality of life of the patients play a key role in the therapeutic process for dNENs, including optimal management approaches and follow-up intervals.



Location, incidence, and malignant potential of duodenal gastrinomas.

The data suggest that a single duodenal wall gastrinoma is a common cause of Zollinger-Ellison syndrome and these small tumors are located in the submucosal layer of the proximal duodenum and are malignant more often than previously thought.

Surgical pathology of gastrinoma. Site, size, multicentricity, association with multiple endocrine neoplasia type 1, and malignancy

Results suggest that duodenal location and multicentricity of gastrinomas are associated with the MEN‐1 syndrome, and solitary gastrinoma, either in the pancreas or the duodenum, are predominantly seen in sporadic ZES.

A Prospective Study of Intraoperative Methods to Diagnose and Resect Duodenal Gastrinomas

It is demonstrated that the duodenum is the most common location for gastrinoma in patients with ZES and that DX to detect and remove duodenal gastrinomas should be routinely performed in all explorations for patients withZES.

Pathologic aspects of gastrinomas in patients with Zollinger-Ellison syndrome with and without multiple endocrine neoplasia type I

In this review, the experience with the pathology of immunocytochemically identified gastrinomas in 44 patients with ZES is presented and related to the relevant literature.

Does the Use of Routine Duodenotomy (DUODX) Affect Rate of Cure, Development of Liver Metastases, or Survival in Patients With Zollinger-Ellison Syndrome?

These results demonstrate that routine use of DUODX increases the short-term and long-term cure rate due to the detection of more duodenal gastrinomas, and should be routinely performed during all operations for cure of sporadic ZES.

Gastrinomas: localization by means of selective intraarterial injection of secretin.

Selective IAS injection, combined with angiography, is the most sensitive study for localizing gastrinomas and avoids percutaneous transhepatic catheterization for portal venous sampling.

Pancreatic tumours as part of the MEN-1 syndrome.

Endocrine tumours of the gastrointestinal tract. Transplantation in the management of metastatic endocrine tumours.

Prospective study of the use of intraarterial secretin injection and portal venous sampling to localize duodenal gastrinomas.

Intraarterial secretin injection is more sensitive than PVS at localizing duodenal gastrinomas and should replace PVS in patients with ZES and occult tumors.